Lv11
30 积分 2026-03-18 加入
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
7小时前
已完结
Beyond MMR Status: The Predictive Value of Immune-Related Adverse Events and Neutrophil-to-Lymphocyte Ratio in Gynecologic Cancer Patients Receiving Pembrolizumab
7小时前
求助中
Prognostic Impact of Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) in advanced-stage ovarian Cancer
7小时前
已关闭
A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer
5个月前
已完结
Association between magnetic resonance imaging-measured bone marrow cellularity and clinical outcomes among patients with cervical cancer treated with programmed cell death protein-1 inhibitors
5个月前
已完结
皖公网安备34019202002308
